Detailed Information on Publication Record
2016
Complex analysis of the p53 tumor suppressor in lung carcinoma
ŠMARDOVÁ, Jana, Květoslava LIŠKOVÁ, Barbora RAVČUKOVÁ, Jitka MALČÍKOVÁ, Jitka HAUSNEROVÁ et. al.Basic information
Original name
Complex analysis of the p53 tumor suppressor in lung carcinoma
Name in Czech
Komplexní analýza nádorového supresoru p53 u plicního karcinomu
Authors
ŠMARDOVÁ, Jana (203 Czech Republic, guarantor, belonging to the institution), Květoslava LIŠKOVÁ (203 Czech Republic), Barbora RAVČUKOVÁ (203 Czech Republic), Jitka MALČÍKOVÁ (203 Czech Republic, belonging to the institution), Jitka HAUSNEROVÁ (203 Czech Republic), Miluše SVITÁKOVÁ (203 Czech Republic), Renata HRABÁLKOVÁ (203 Czech Republic), Lenka ZLÁMALÍKOVÁ (203 Czech Republic), Kateřina STAŇO KOZUBÍK (203 Czech Republic, belonging to the institution), Ivona BLAHÁKOVÁ (203 Czech Republic, belonging to the institution), Jana ŠPELDOVÁ (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution) and Jan ŠMARDA (203 Czech Republic, belonging to the institution)
Edition
Oncology Reports, National Hellenic Research Foundation, 2016, 1021-335X
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
10601 Cell biology
Country of publisher
Greece
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 2.662
RIV identification code
RIV/00216224:14310/16:00089204
Organization unit
Faculty of Science
UT WoS
000368228900075
Keywords (in Czech)
plicní adenokarcinom; nádorový supresor p53; FASAY; FISH; mutace TP53
Keywords in English
lung adenocarcinoma; p53 tumor suppressor; FASAY; FISH; TP53 mutation
Tags
International impact, Reviewed
Změněno: 19/2/2018 11:26, prof. RNDr. Jan Šmarda, CSc.
Abstract
V originále
Lung cancer is the leading cause of cancer-related deaths worldwide. Mutations of the TP53 gene occur very frequently in lung carcinomas and they play an important role in both oncogenic transformation of lung epithelial cells and lung carcinoma progression. We determined the TP53 status in 42 samples of squamous cell lung carcinoma (SQCC) and 56 samples of lung adenocarcinoma (AC) by the functional analysis FASAY and its variant called split assay. Altogether, we detected 64 TP53 mutations in 63 patients and analyzed them by cDNA and gDNA sequencing. The TP53 mutations were found in 76.2% (32/42) of SQCC cases, and 55.4% (31/56) of ACs. Immunoblotting revealed the p53 protein accumulation in 18 samples (42.9%) among SQCC cases and 19 samples (33.9%) among AC cases. Using fluorescence in situ hybridization we detected loss of the TP53-specific 17p13.3 locus in 23 from 41 analyzed SQCC samples (56.1%) and in 20 from 54 analyzed AC samples (37.0%). We did not find any statistically significant differences in overall and disease-free survival in relation to TP53 status.